Statements (68)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:psychologist
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:HSV-1
|
| gptkbp:affects |
gptkb:Person
adults memory loss cognitive impairment personality changes seizure disorders motor deficits |
| gptkbp:associated_with |
gptkb:HSV-1
gptkb:HSV-2 herpes genitalis herpes labialis |
| gptkbp:casualties |
higher in elderly
higher in infants higher in immunocompromised individuals |
| gptkbp:caused_by |
gptkb:herpes_simplex_virus
|
| gptkbp:clinical_trial |
nausea
vomiting ataxia ongoing studies tremors dysphagia coma hypotonia hyperreflexia rapid onset photophobia dysphasia altered mental status focal neurological deficits phonophobia |
| gptkbp:complications |
gptkb:cemetery
neurological damage |
| gptkbp:distribution |
worldwide
|
| gptkbp:duration |
2-3 weeks
|
| gptkbp:end_of_life |
20-30% without treatment
7-20% with treatment |
| gptkbp:events |
rehabilitation
neurological assessment |
| gptkbp:first_described_by |
1930s
|
| gptkbp:healthcare |
gptkb:battle
|
| https://www.w3.org/2000/01/rdf-schema#label |
herpes simplex encephalitis
|
| gptkbp:is_a_route_for |
inflammation of the brain
|
| gptkbp:is_often_used_in |
young adults
elderly |
| gptkbp:is_protected_by |
no vaccine available
|
| gptkbp:occurs_in |
1-2 cases per 100,000 people
|
| gptkbp:public_awareness |
ongoing
|
| gptkbp:research_focus |
gptkb:vaccine
vaccine development |
| gptkbp:risk_factor |
age
immunocompromised state |
| gptkbp:scholarships |
gptkb:stock_market_index
|
| gptkbp:social_responsibility |
gptkb:EEG
MRI scan PCR test lumbar puncture seasonal variation neurotropic virus |
| gptkbp:symptoms |
headache
fever confusion seizures |
| gptkbp:transmission |
not contagious
|
| gptkbp:treatment |
gptkb:drug
supportive care |